Good MorningEquity markets fell for the 2nd day as traders assessed the latest economic data and FOMC activity. The takeaway is that inflation puts the economy on the brink of an actual recession, and the FOMC is still raising interest rates. The committee wants to ensure inflation is tamed, which will most likely trigger the recession everyone fears. Regardless, the S&P 500 is in the first inning of what could be a prolonged earnings recession that has been sparked by a decline in volume brought on by high prices and high-interest rates.
Friday's action will be critical for the market. The S&P 500 index confirms the presence of resistance at the 41,50 level, which may lead to another big sell-off. The rally may continue if the market can rebound and close even near the week's high. If not, investors should brace for another sell-off that could shave 15% to 20% off of the major indices by the start of spring. January effect or not, the outlook for S&P 500 earnings is moving lower, leading the market lower. Featured: 5 dividend stocks worth owning in any market condition (Ad) 
|
Consumer Discretionary | |
Reynolds Consumer Products (NASDAQ: REYN) share price has struggled to gain traction since the IPO, but one thing is certain. When the share prices drop below $27.75, someone in the market steps in and buys them, which is happening now. The Q1 guidance and outlook for the year are a little on the... Read the Full Story |
|
From Our Partners | | Renewed tensions involving Iran are putting global oil supplies back in focus - and history shows certain energy stocks respond before the broader market catches on.
A new report identifies three energy stocks emerging from today's supply disruptions. One is already benefiting from the current environment; the other two may not be on your radar yet. | | See which three energy stocks made the list and why they stand out |
|
Consumer Staples | |
The price action in PepsiCo Inc. (NASDAQ: PEP) pulled back from a high recently, but this weakness in the action offers a buying opportunity in a Dividend King. PepsiCo's Q4 results prove the company's strategy continues to work and has what it takes to succeed in today's market: brand strength an... Read the Full Story |
|
Consumer Discretionary | |
It’s never too late for a curtain call.
Some stocks partied like rock stars coming off the March 2020 market bottom. As doomsday pandemic fears faded, it was the most risky (and often least profitable) companies that took center stage. Meme stocks and SPACs stole the show with some outrageo... Read the Full Story |
|
From Our Partners | | Most AI portfolios hold the same handful of chip and software names - and completely ignore the physical layer. One perception-hardware company posted ~49% Q1 revenue growth with four partnership announcements in a single month.
A free report names seven companies building the automation, robotics, and semiconductor-test infrastructure that AI requires to move beyond the data center - including an automation giant that raised full-year guidance after quarterly sales rose ~12%. | | Click here to get your free copy of this report today |
|
Consumer Discretionary | |
Shares of The Walt Disney Company (NYSE: DIS) have been on a roller coaster ride for the last few years, leaving investors less than enthused. The latest twist in the ride, however, included the renaming of Bob Iger to the helm, a move that is getting lots of positive attention.
The question now ... Read the Full Story |
|
Auto/Tires/Trucks | |
Looking for information about Harley Davidson and HOG stock dividend? Harley Davidson is an iconic brand with a regular dividend payment that you might want to pop into your portfolio.
By the time you reach the end of this article, you will know what you need to make an informed decision. The ta... Read the Full Story |
|
From Our Partners | | Trader Graham Lindman has built a strategy around a repeating anomaly that appears in the first 60 minutes of every trading day - and it never requires holding positions overnight.
The setup has recently been refined to target up to 100% payouts by holding through the close, with 10 consecutive winning trades logged during one of the most volatile stretches since the Tariff Wars.
A new signal opportunity opens tomorrow. | | See how to join Graham Lindman's next trade before it opens |
|
Markets | |
It's a regular occurrence. Penny stocks always dominate the top daily gainers and losers lists, often skyrocketing 50% or more in a single day. But the rapid price appreciation is usually followed by an equally dramatic crash in the price.
And you can probably picture these charts in your head. T... Read the Full Story |
|
Finance | |
The January non-farm payrolls report was much stronger than expected, and the market cheered. The takeaway, at first glance, is that the economy is doing well while inflation is cooling, but this is a dubious take on the economy.
The labor data arguably is little more than a coincident indicator ... Read the Full Story |
|
Consumer Discretionary | |
With shares having rallied nearly 30% since last November’s low, there are signs of a recovery rally truly taking off with Take-Two Interactive Software, Inc.’s (NASDAQ: TTWO) stock. Having fallen pretty much double that from its 2021 high, it’s a much-welcomed uptrend for invest... Read the Full Story |
|
Consumer Staples | |
Campbell Soup Co. (NYSE: CPB) was among the U.S. large caps that bucked the bear market of 2022. With defensive names in favor, the soup and snacks maker was also one of few S&P 500 stocks that finished the year up at least 30%.
But after reaching an intraday high of $57.78 shortly after Chri... Read the Full Story |
|
Technology | |
The S&P 500 tech sector is up 18.65% in the past month, with sector component Fortinet (NASDAQ: FTNT) gapping up 12% on February 8.
The cybersecurity specialist was the sector’s best price performer in the session, with SolarEdge Technologies Inc. (NASDAQ: SEDG), First Solar Inc. (NASD... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. | | View Today's Stock Pick |
|
